Dialyzability of faropenem sodium during hemodialysis in patients with chronic renal failure
Not Applicable
- Conditions
- Chronic renal failure, infection
- Registration Number
- JPRN-UMIN000019365
- Lead Sponsor
- Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University
- Brief Summary
The elimination ratio of faropenem by hemodialysis was small as about 20%; In the 29th Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (Tokyo, Dec 4th -6th, 2008)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with poorly controlled diabetes (HbA1c 7.0% or more) 2. Patients with hepatic failure 3. Patients have a history of allergy to beta-lactam antibiotics 4. Patients have been taking faropenem within one week 5. Patients taking sodium valproate 6. Patients taking warfarin 7. Pregnant women and nursing woman 8. Judged inappropriate to participate in this study by a doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hemodialysis clearance of faropenem
- Secondary Outcome Measures
Name Time Method